Figure 1. Patterns of HER2–PET/CT confronted with FDG–PET/CT, Maximum intensity projection. Lesion uptake was considered pertinent when visually higher.

Slides:

Advertisements

Similar presentations

How to manage suspected cancer

Advertisements

From: An open day in the metric space

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 1 Flow chart of the COBRA-light trial and its extension study

From: Global Banking: Recent Developments and Insights from Research*

Figure 2. Quality of life (QOL) scores for functional scale items

Fig. 1 Graphical representation

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.

Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.

Figure 2. CONSORT flow diagram.

Figure 1. Raw mean scores of the MFI subscales ‘mental fatigue’ and ‘reduction in motivation’ (range 4–20, the higher the score the more mental fatigue.

pSS: primary SS; Scl: scleroderma.

Figure 6 Case 6: (A) MRA showed occlusion of the left internal carotid artery. (B) MRI 4 days before cell injection and (C) 7 days after cell injection.

Figure 1. Selection of papers.

Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Fig. 1 Flow of ascertainment of cases with incident childhood IgA vasculitis reported by four sources From: Incidence of IgA vasculitis in children estimated.

Figure 2. Illustration of minimum cross-sectional area (a) and measurements for oropharynx and soft palate in sagittal plane (b, c). From: Airway volume.

From: Unmasking Masks in Makkah: Preventing Influenza at Hajj

Figure 1 (A) Chest computed tomography scans of the patient

Figure 2. (A) Sézary syndrome patient before treatment

Figure 2. Kaplan–Meier survival analysis in patients

Figure 1 Overview of the IMPACT Analysis Pipeline

Fig 1 Perfusion index values at different time intervals in patients with successful and failed blocks. A reference line at PI 3.3 is provided. Horizontal.

Figure 1 Flow chart showing the selection of publications identified in the literature search. From: GnRH antagonist versus long agonist protocols in IVF:

From: Where do we go from here

Figure 1. Overall survival of patients receiving alternative medicine (solid lines) vs conventional cancer treatment (dashed lines). Overall survival of.

Example 14. Schubert, Quartet in G Major, D

Figure 1. Single-Tree Model and BART Fits to Simulated Data.

Fig. 1 Selection of patients

Fig. 1 Flow diagram of patient selection and study design.

Figure 1. Academic productivity and high academic income: top earners vs. the rest of academics. The average number of ‘peer-reviewed article equivalents’

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Figure 1. Examples of e-cigarette discussions in social media

From: Estimating the Location of World Wheat Price Discovery

Figure 3. Hypothalamic–Pituitary–Adrenal (HPA)-axis functioning moderates crime exposure: regions of significance on X (crime). The lines represent two.

Figure 1. Time of initiation of therapeutic hypothermia according to who initiated it. Note the logarithmic scaling of the vertical axis. From: Initiation.

Figure 1: Time points at which sperm samples were analysed for aneuploidy frequencies in controls and cancer patients From: Sperm aneuploidy frequencies.

Figure 1: Logistic regression showing association of prescribing provider and patient panel characteristics with occurrence of a hospitalization or ED.

Figure 3. Visualisation of ESMO-MCB scores for curative and non-curative setting. A & B and 5 and 4 represent the grades with substantial improvement.

Figure 1. Dosage and administration route of drugs used in the BMD study. Each cycle was proposed every 28 days (‘base’ schedule) or 35 days (‘weekly’

Figure 1 Study flow chart

Figure 2 Comparison of pregnancy outcomes between true NC-FET and modified NC-FET. Odds ratio (OR) adjusted for clinical pregnancy (OR 0.90, 95% CI 0.73–1.12)

Figure 3. Proposed algorithm of treatment for patients with a diagnosis of PI [prepouch ileitis]. From: Prepouch Ileitis After Ileal Pouch-anal Anastomosis:

Figure 1. (A) Cumulative risk of breast (diamonds) and ovarian (squares) cancer in BRCA1 mutation carriers. (B) Cumulative risk of breast (diamonds) and.

Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.

توزیع جغرافیایی مرگ به دلیل بدخیمی در کشور Age-standardized incidence rate of all cancers per 100 000 in female in Iran 2005–2006.

Figure 1. Bar plots of age-standardized (world population) death rates per 100 000 persons for the year 2014 (blue, ... Figure 1. Bar plots of age-standardized.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Take home figure The protective role of CNP/NPR-B/NPRC.

Fig. 1 Flow chart of included patients for analyses

Figure 1. Survival curves from a hypothesized clinical trial randomizing patient to standard of care with and without ... Figure 1. Survival curves from.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. Relationships among microsatellite instability (MSI; letter A indicates the group with MSI), high tumour ... Figure 1. Relationships among microsatellite.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. Oncoprint of selected pathogenic alterations detected in ctDNA. Unless provided in the caption above, the following copyright applies to the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 2. Biomarkers for prediction of differences in PFS and objective response rate between GP and GT arm in patients ... Figure 2. Biomarkers for prediction.

Figure 1. Longitudinal measures of HIV persistence and immunologic phenotype/function during anti-PD-1 therapy are ... Figure 1. Longitudinal measures.

Figure 1 Grant agencies and charitable foundations supporting Plan S.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. A summary of phase 3 trials for previously untreated advanced/metastatic NSCLC. AEs, adverse events; Beva, ... Figure 1. A summary of phase 3.

Figure 2. Forest plot of multivariable Cox proportional hazard regression illustrating the impact of chemoradiation ... Figure 2. Forest plot of multivariable.

Figure 1: Trade shares of South Korea's major trading partners (% of South Korea's total trade in goods) Figure 1: Trade shares of South Korea's major.

Figure 1 ABCDE of primary prevention.2

Figure 1. Forest plot of lung cancer mortality in LDCT trials.

Figure 1. Heterogeneous HER2 immunostaining in two gastric cancer samples classified as HER2 3+. (A) Complete ... Figure 1. Heterogeneous HER2 immunostaining.

Presentation transcript:

Figure 1. Patterns of HER2–PET/CT confronted with FDG–PET/CT, Maximum intensity projection. Lesion uptake was considered pertinent when visually higher than blood pool. (A) Entire tumor load showed pertinent tracer uptake; (B) dominant part of tumor load showed tracer uptake; (C) minor part of tumor load showed tracer uptake; (D) entire tumor load lacked tracer uptake. From: Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial Ann Oncol. 2015;27(4):619-624. doi:10.1093/annonc/mdv577 Ann Oncol | © The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 1